BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 10, 2017
View Archived Issues
Lundbeck recaps progress of fourth quarter 2016
Read More
ASLAN Pharmaceuticals presents phase II results for varlitinib
Read More
Treatment with MD-1003 shows efficacy and safety in patients with progressive multiple sclerosis
Read More
Promising inhibitors of STOML3 oligomerization in treating tactile-driven pain following neuropathy
Read More
Kagoshima University identifies novel anti-hepatitis B virus agents
Read More
Neurocrine and Bial sign licensing agreement for opicapone in U.S. and Canada
Read More
SC-83288, a clinical development candidate with novel mode of action for the treatment of malaria
Read More
Update on phase III trials of NC-6004 for the treatment of pancreatic cancer
Read More
CEVEC Pharmaceuticals signs agreement with NewLink Genetics for use of its cell lines
Read More
Phase I results show UE-2343 is brain penetrant and well tolerated
Read More
Armetheon agrees with FDA on phase III study for oral anticoagulant
Read More
Tracon reports phase II topline results for TRC-105 in recurrent glioblastoma
Read More
Marathon Pharmaceuticals' Emflaza approved by FDA for DMD
Read More
Viking Therapeutics reports results on VK-2809 in model of GSD Ia
Read More
MRC, South African MRC and GSK partner to tackle noncommunicable diseases in Africa
Read More
MediWound reports favorable results from phase II study of NexoBrid
Read More
Ovid Therapeutics enters Angelman syndrome biomarker collaboration, begins phase II study
Read More
Tessa Therapeutics and A*STAR's IMCB collaborate on immuno-oncology lab
Read More
Copanlisib named FDA orphan drug for splenic, nodal and extranodal marginal zone lymphoma
Read More
FDA names laquinimod sodium an orphan drug for Huntington's disease
Read More
Generex continues process to acquire controlling equity interest in Emmaus Life Sciences
Read More
U.S. orphan drug designation granted to IMG-7289 for acute myeloid leukemia
Read More
Blood NF-L, a promising biomarker for differential diagnosis of parkinsonian disorder
Read More
Systems Oncology signs license agreement with University of Wisconsin-Milwaukee
Read More
Prevacus plans phase I studies of PRV-002 to treat concussion
Read More
Boehringer Ingelheim starts phase II trial to treat advanced squamous cell carcinoma of the lung
Read More